A closely watched trial that many hoped would help clarify a contentious battle over access to generic drugs instead ended in disappointment last week In fact the outcome only seems to have underscored the difficulty in sorting out socalled paytodelay deals a topic that has embroiled the pharmaceutical industry regulators and the courts for years The case decided last weekin which AstraZeneca PLC and Ranbaxy Laboratories Ltd were accused of illegally delaying a generic version of AstraZenecas Nexium heartburn pilloffered the prospect of some muchneeded clarity since it was the first to go to trial since the ruling Instead the federal court jury in Boston offered a mixed bag